NCT02461914View on ClinicalTrials.gov

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 1, 2015

Primary Completion Date

December 12, 2015

Study Completion Date

July 13, 2016

Conditions
Healthy
Interventions
DRUG

PEX168

200µg,injected subcutaneously,once a week.

DRUG

Warfarin

5mg,oral,two times.

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY